Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A critical approximation to the use of cost-effectiveness evaluation for Vaccines inclusion in Immunization Programs: the case of pneumococcal vaccines in Latin America ; Aproximación crítica al uso de evaluaciones de costo-efectividad para inclusión de vacunas en los programas nacionales de inmunización: el caso de la vacunación contra neumococo en Latinoamérica

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      De la Hoz-Restrepo, Fernando Pio; Grupo de Epidemiología y Evaluación en Salud Pública; orcid:0000-0002-8735-6223; https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001124145; 35769124700; https://www.researchgate.net/profile/Carlos-Castaneda-Orjuela; https://scholar.google.com/citations?user=XESiWzMAAAAJ&hl=es&oi=ao
    • بيانات النشر:
      Universidad Nacional de Colombia
      Bogotá - Medicina - Doctorado en Salud Pública
      Doctorado Interfacultades en Salud Pública
      Facultad de Medicina
      Bogotá,Colombia
      Universidad Nacional de Colombia - Sede Bogotá
    • الموضوع:
      2023
    • نبذة مختصرة :
      ilustraciones ; Background: Worldwide, vaccination is considered a very successful and cost-effective pu- blic health strategy to prevent a wide range of communicable diseases, especially in children. New vaccines are available but at higher costs than those originally included in the basic Expanded Program on Immunization (EPI). Latin American and the Caribbean (LAC) is a region with a great commitment with the inclusion of new vaccines, supported mainly by the Pan American Health Organization (PAHO), however, budget impact of universal immunization is still a challenge for national EPIs. The present research considered both po- sitive and normative dimensions of decision making (DM) in health, particularly in settings with limited resources such as LAC countries, to explore the key rationalities considered to make investment decisions in public health. Pneumococcal conjugated vaccines (PCVs) were selected for the case study to approximate the way in that DM are done at national EPIs with public funds. The exploration of DM frameworks in public health, particularly in low- and middle-income countries (LMIC) settings, is very scarce in the scientific litera- ture, but health-care system around the world are continuously choosing and financing new interventions. It is important to approach to the rationalities involved in the DM process, to evaluate the knowledge of the stakeholders about the arguments and evaluations exposed in the discussion, and to propose improvements in the DM from a democratic perspective. An advance in this sense could give to public health practitioners several tools to guarantee better decisions and more points of view to be included in the discussion, as well as identify potential pitfalls of the available methods, most of them from an utilitarian perspective, to inform the DM in public health. Aim: To critically address how PCVs have been included in the EPIs and the role played by the economic evaluations of their introduction in low- and middle-income countries from the LAC region. ...
    • File Description:
      xxi, 42 páginas; application/pdf
    • Relation:
      Baker L, Birnbaum H, Geppert J, Mishol D, Moyneur E. The relationship between technology availability and health care spending. Health Aff (Millwood). 2003;Suppl Web Exclusives:3-537. [DOI:10.1377/hlthaff.w3.537] [PubMed:15506158].; Lehoux P, Blume S. Technology assessment and the sociopolitics of health technologies. J Health Polit Policy Law. 2000 Dec;25(6):1083-120. [DOI:10.1215/03616878-25-6-1083] [PubMed:11142053].; Lehoux P. The Problem of Health Technology: Policy Implications for Modern Health Care Systems. London: Routledge; 2006.; Orton L, Lloyd-Williams F, Taylor-Robinson D, O’Flaherty M, Capewell S. The use of research evidence in public health decision making processes: sys- tematic review. PLoS One. 2011;6(7):e21704. [PubMed Central:PMC1120888] [DOI:10.1371/journal.pone.0021704] [PubMed:15128705].; World Health Organization. Evidence, policy, impact. WHO guide for evidence-informed decision-making. World Health Organization; 2021. Accessed: 2023-06-10. https:// www.who.int/publications/i/item/9789240039872.; Brouwer WB, Koopmanschap MA. On the economic foundations of CEA. La- dies and gentlemen, take your positions! J Health Econ. 2000 Jul;19(4):439-59. [DOI:10.1016/s0167-6296(99)00038-7] [PubMed:11010234].; Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford: Oxford University Press; 2015.; Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: de- sign, definitions, and metrics. Lancet. 2012 Dec;380(9859):2063-6. [DOI:10.1016/S0140- 6736(12)61899-6] [PubMed:23245602].; Marangu D, Zar HJ. Childhood pneumonia in low-and-middle-income countries: An update. Paediatr Respir Rev. 2019 Nov;32:3-9. [PubMed Central:PMC6990397] [DOI:10.1016/j.prrv.2019.06.001] [PubMed:28282701].; Quirk SJ, Haraldsson G, Hja ́lmarsd ́ottir MA, van Tonder AJ, Hrafnkelsson B, Bentley SD, et al. Vaccination of Icelandic Children with the 10-Valent Pneumococcal Vac- cine Leads to a Significant Herd Effect among Adults in Iceland. J Clin Microbiol. 2019 Apr;57(4). [PubMed Central:PMC4688572] [DOI:10.3109/00365548.2014.980842] [PubMed:25664503].; Jauregui B, Janusz CB, Clark AD, Sinha A, Garcia AG, Resch S, et al. ProVac Glo- bal Initiative: a vision shaped by ten years of supporting evidence-based policy deci- sions. Vaccine. 2015 May;33 Suppl 1:A21-7. [DOI:10.1016/j.vaccine.2014.12.080] [Pub- Med:25919164].; Glassman A, n O, Silverman R. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America. Value Health. 2016 Dec;19(8):913-20. [PubMed Central:PMC5193154] [DOI:10.1016/j.jval.2016.04.014] [PubMed:25919155].; Agudelo CI, Castan ̃eda Orjuela C, Brandileone MCC, Echa ́niz-Aviles G, Almeida SCG, Carnalla-Barajas MN, et al. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study. Lancet Infect Dis. 2021 03;21(3):405-17. [DOI:10.1016/S1473-3099(20)30489-8] [PubMed:32986996].; Nieto Guevara J, Borys D, DeAntonio R, Guzman-Holst A, Hoet B. In- terchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert Rev Vaccines. 2020 Nov;19(11):1011-22. [DOI:10.1080/14760584.2019.1688148] [PubMed:31751159].; de Oliveira LH, Trumbo SP, Ruiz Matus C, Sanwogou NJ, Toscano CM. Pneu- mococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. Expert Rev Vaccines. 2016 Oct;15(10):1295-304. [DOI:10.1586/14760584.2016.1166961] [PubMed:26982434].; de Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, Ruiz-Matus C, Tambini G, An- drus JK. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. Pediatr Infect Dis J. 2011 Jan;30(1 Suppl):S61-6. [DOI:10.1097/INF.0b013e3181fefdd6] [PubMed:21183843].; Toscano CM, Jauregui B, Janusz CB, Sinha A, Clark AD, Sanderson C, et al. Esta- blishing a regional network of academic centers to support decision making for new vac- cine introduction in Latin America and the Caribbean: the ProVac experience. Vaccine. 2013 Jul;31 Suppl 3:C12-8. [DOI:10.1016/j.vaccine.2013.05.033] [PubMed:23777685].; de Oliveira LH, Toscano CM, Sanwogou NJ, Ruiz-Matus C, Tambini G, Roses- Periago M, et al. Systematic documentation of new vaccine introduction in selec- ted countries of the Latin American Region. Vaccine. 2013 Jul;31 Suppl 3:C114-22. [DOI:10.1016/j.vaccine.2013.05.032] [PubMed:23777684].; Donadel M, Panero MS, Ametewee L, Shefer AM. National decision-making for the introduction of new vaccines: A systematic review, 2010-2020. Vaccine. 2021 Apr;39(14):1897-909. [DOI:10.1016/j.vaccine.2021.02.059] [PubMed:33750592].; Kuhn TS. The Structure of Scientific Revolutions. Chicago: University of Chicago Press; 1962.; Byford S, Raftery J. Perspectives in economic evaluation. BMJ. 1998 May;316(7143):1529-30. [PubMed Central:PMC1113167] [DOI:10.1136/bmj.316.7143.1529] [PubMed:7780526].; Robinson R. Economic evaluation and health care. What does it mean? BMJ. 1993 Sep;307(6905):670-3. [PubMed Central:PMC1678982] [DOI:10.1136/bmj.307.6905.670] [PubMed:1778701].; Birch S, Gafni A. Cost-Effectiveness and Cost Utility Analyses: Methods for the Non- Economic Evaluation of Health Care Programmes and How We Can Do Better. In: Geisler E, Heller O, editors. Managing Technology in Healthcare. Boston, MA: Springer US; 2006. Consulted 2015 Oct 20. Available from: http://www.springerlink.com/ index/10.1007/978-1-4613-1415-8.; Contandriopoulos AP, Champagne F, Denis JL, Avargues MC. [Evaluation in the health sector: concepts and methods]. Rev Epidemiol Sante Publique. 2000 Dec;48(6):517-39. [PubMed:11148425].; EUnetHTA. Common questions;. Consulted 2017 Mar 25. Available from: http://www. eunethta.eu/about-us/faq#t287n73.; Institute of Medicine. Assessing Medical Technologies. Washington D.C: National Academy Press; 1985.; Hofmann B. Why not integrate ethics in HTA: identification and assessment of the reasons. GMS Health Technol Assess. 2014;10:Doc04. [PubMed Central:PMC3736275] [DOI:10.1017/S0266462308080550] [PubMed:18828936].; Diamond GA, Kaul S. Cost, effectiveness, and cost-effectiveness. Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):49-54. [DOI:10.1161/CIRCOUTCOMES.108.793406] [Pub- Med:20031812].; Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circ Cardio- vasc Qual Outcomes. 2009 Jan;2(1):55-8. [DOI:10.1161/CIRCOUTCOMES.108.812321] [PubMed:20031813].; Morabia A. A History of Epidemiologic Methods and Concepts. Springer Basel AG; 2004.; Carlos Castañeda-Orjuela, Fernando De la Hoz-Restrepo. Criteria for New Vaccine Introduction in a National Expanded Program on Immunization: A Survey of Expanded Program on Immunization Managers. Value in Health Regional Issues, Volume 31, 2022, Pages 142-147, ISSN 2212-1099, https://doi.org/10.1016/j.vhri.2022.05.001 (https://www.sciencedirect.com/science/article/pii/S2212109922001169).; Carlos Castañeda-Orjuela, Mario García-Molina, Fernando De la Hoz-Restrepo. Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making? Value in Health Regional Issues. Volume 23, 2020, Pages 1-5, ISSN 2212-1099, https://doi.org/10.1016/j.vhri.2019.09.009 (https://www.sciencedirect.com/science/article/pii/S2212109919306193).; Castañeda-Orjuela C, De la Hoz-Restrepo F. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine (2018), ISSN 0264-410X, https://doi.org/10.1016/j.vaccine.2018.07.078 (https://www.journals.elsevier.com/vaccine).; Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Strep- tococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018 Jul;6(7):e744-57. [PubMed Central:PMC3192903] [DOI:10.1016/S2214- 109X(18)30247-X] [PubMed:20417415].; Walter EB, Smith MJ. Prevention of pneumococcal infections in childhood: two decades of progress. Curr Opin Pediatr. 2022 Apr;34(2):140-6. [DOI:10.1097/MOP.0000000000001112] [PubMed:35232949].; Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019 02;18(2):119-31. [DOI:10.1080/14760584.2019.1574224] [PubMed:30689472].; Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A, et al. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparati- ve assessment of decision-making tools. BMC Med. 2011 May;9:53. [PubMed Cen- tral:PMC1188116] [DOI:10.1136/bmj.331.7514.446] [PubMed:16110075].; Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford; 2006.; Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013 Mar;346:f1049. [DOI:10.1136/bmj.f1049] [PubMed:23529982].; World Bank. World Bank Open Data;. Accessed: 2022-09-15. https://data. worldbank.org.; Sinha A, Constenla D, Valencia JE, O’Loughlin R, Gomez E, de la Hoz F, et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publica. 2008 Nov;24(5):304-13. [DOI:10.1590/s1020-49892008001100002] [PubMed:19141172].; Constenla DO. Economic impact of pneumococcal conjugate vaccination in Bra- zil, Chile, and Uruguay. Rev Panam Salud Publica. 2008 Aug;24(2):101-12. [DOI:10.1590/s1020-49892008000800004] [PubMed:19062601].; Vespa G, Constenla DO, Pepe C, Safadi MA, Berezin E, de Moraes JC, et al. Es- timating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publica. 2009 Dec;26(6):518-28. [DOI:10.1590/s1020-49892009001200007] [PubMed:20107706].; de Souza C, Ribeiro J, Moraes J, Berezin E, Monteiro R, Presa J. Ana ́lise de custo efetividade da vacina pneumoc ́ocica conjugada 7-valente, na prevenc ̧ ̃ao da doen ̧ca pneu- moc ́ocica, no cena ́rio do SSistema U ́nico de Sau ́de. J Bras Econ Sau ́de. 2009;1(1):11-7.; de Souza C, Moraes J, Berezin E, Monteiro R, Presa J, Almeida G. An ́alise de cus- to efetividade da vacina pneumoco ́cica conjugada 13-valente, na preven ̧c ̃ao da doen ̧ca pneumoco ́cica, no cena ́rio do Sistema U ́nico de Sau ́de - SUS. Ana ́lise econoˆmica da vacina pneumoco ́cica. J Bras Econ Sau ́de. 2009;1(3):103-11.; Giglio ND, Cane AD, Micone P, Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 2010 Mar;28(11):2302- 10. [DOI:10.1016/j.vaccine.2009.12.070] [PubMed:20064478].; Talbird SE, Taylor TN, Knoll S, Frostad CR, Garc ́ıa Mart ́ı S. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010 Nov;28 Suppl 6:G23-9. [DOI:10.1016/j.vaccine.2010.06.016] [PubMed:21075266].; Giachetto Larraz G, Telechea Ortiz H, Speranza Mourine N, Giglio N, Can ́e A, P ́ırez Garc ́ıa MC, et al. [Cost-effectiveness of universal pneumococcal vaccination in Uruguay]. Rev Panam Salud Publica. 2010 Aug;28(2):92-9. [DOI:10.1590/s1020- 49892010000800004] [PubMed:20963275].; Uruen ̃a A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011 Jul;29(31):4963-72. [DOI:10.1016/j.vaccine.2011.04.111] [PubMed:21621575].; Mucin ̃o-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjuga- ted vaccines]. Value Health. 2011;14(5 Suppl 1):65-70. [DOI:10.1016/j.jval.2011.05.025] [PubMed:21839902].; Sartori AM, de Soa ́rez PC, Novaes HM. Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J Epidemiol Community Health. 2012 Mar;66(3):210-7. [DOI:10.1136/jech.2010.111880] [PubMed:20884668].; Castan ̃eda Orjuela C, Alvis-Guzm ́an N, Velandia-Gonza ́lez M, De la Hoz- Restrepo F. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 2012 Mar;30(11):1936-43. [DOI:10.1016/j.vaccine.2012.01.031] [PubMed:22266291].; Mart ́ı SG, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, et al. A cost- effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc. 2013 Aug;11(1):21. [PubMed Cen- tral:PMC3766226] [DOI:10.1186/1478-7547-11-21] [PubMed:16275962].; Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O. Cost- effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in chil- dren of Peru. BMC Public Health. 2013 Oct;13:1025. [PubMed Central:PMC4228443] [DOI:10.1186/1471-2458-13-1025] [PubMed:21075268].; Mezones-Holgu ́ın E, Bolan ̃os-D ́ıaz R, Fiestas V, Sanabria C, Guti ́errez-Aguado A, Fies- tas F, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccines in pre- venting pneumonia in Peruvian children. J Infect Dev Ctries. 2014 Dec;8(12):1552-62. [DOI:10.3855/jidc.5855] [PubMed:25500653].; Ord ́on ̃ez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal con- jugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015;13:6. [PubMed Central:PMC4397735] [DOI:10.1186/s12962-015-0032-1] [Pub- Med:22284997].; Constenla DO. Post-introduction economic evaluation of pneumococcal conjugate vaccination in Ecuador, Honduras, and Paraguay. Rev Panam Salud Publica. 2015 Nov;38(5):388-95. [PubMed:26837524].; Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Ja ́uregui B, Janusz CB, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Vaccine. 2015 May;33 Suppl 1:A143-53. [DOI:10.1016/j.vaccine.2014.12.078] [Pub- Med:25919155].; Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jau ́regui B, Escobedo- Palza S, et al. Cost-effectiveness analysis of 10- and 13-valent pneumo- coccal conjugate vaccines in Peru. Vaccine. 2015 May;33 Suppl 1:A154-66. [DOI:10.1016/j.vaccine.2014.12.039] [PubMed:25919156].; G ́omez JA, Villasen ̃or-Sierra A, Aguilar GM, Manjarrez RC, Cervantes-Apolinar MY. Estimaci ́on de la Relacio ́n Costo-Efectividad de las Vacunas Neumoco ́cicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacuna- cio ́n de Poblaci ́on Infantil Mexicana. Value Health Reg Issues. 2016 Dec;11:76-84. [DOI:10.1016/j.vhri.2016.07.009] [PubMed:27986203].; Wasserman M, Palacios MG, Grajales AG, Baez/Revueltas FB, Wilson M, Mc- Dade C, et al. Modeling the sustained use of the 13-valent pneumococ- cal conjugate vaccine compared to switching to the 10-valent vaccine in Mexi- co. Hum Vaccin Immunother. 2019;15(3):560-9. [PubMed Central:PMC6605727] [DOI:10.1080/21645515.2018.1516491] [PubMed:28216181].; Pugh S, Wasserman M, Moffatt M, Marques S, Reyes JM, Prieto VA, et al. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vac- cine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis. Infect Dis Ther. 2020 Jun;9(2):305-24. [PubMed Central:PMC7237584] [DOI:10.1007/s40121- 020-00287-5] [PubMed:22085813].; Garc ́ıa Farin ̃as A, Linares-P ́erez N, Clark A, Toledo-Roman ́ı M, El Omeiri N, Marre- ro Arau ́jo M, et al. Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme. Int J Infect Dis. 2020 Aug;97:182-9. [DOI:10.1016/j.ijid.2020.05.078] [PubMed:32474199].; Perdrizet J, Santana CFS, Senna T, Alexandre RF, Sini de Almeida R, Spinardi J, et al. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil in- fants. Hum Vaccin Immunother. 2021 04;17(4):1162-72. [PubMed Central:PMC8018448] [DOI:10.1080/21645515.2020.1809266] [PubMed:18923713].; World Health Organization. Macroeconomics and health: investing in health for econo- mic development. Report of the Commission on Macroeconomics and Health. Washing- ton: World Health Organization; 2001.; Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Re- view of vaccine effectiveness assumptions used in economic evaluations of in- fant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018 Jan;17(1):71-8. [DOI:10.1080/14760584.2018.1409116] [PubMed:29164952].; Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022 01;376:e067975. [PubMed Central:PMC8749494] [DOI:10.1136/bmj-2021-067975] [PubMed:33728553].; Cross S, Rho Y, Reddy H, Pepperrell T, Rodgers F, Osborne R, et al. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? BMJ Glob Health. 2021 12;6(12). [PubMed Central:PMC8704023] [DOI:10.1136/bmjgh-2021-007321] [Pub- Med:26726926].; Huang L, Wasserman M, Grant L, Farkouh R, Snow V, Arguedas A, et al. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine. 2022 Aug;40(33):4700- 8. [DOI:10.1016/j.vaccine.2022.06.024] [PubMed:35753839].; Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530-9. [Pub- Med Central:PMC6605726] [DOI:10.1080/21645515.2018.1532249] [PubMed:23440780].; Thompson A, Lamberth E, Severs J, Scully I, Tarabar S, Ginis J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019 09;37(42):6201-7. [DOI:10.1016/j.vaccine.2019.08.048] [PubMed:31495592].; Silva PH, Va ́zquez Y, Campusano C, Retamal-D ́ıaz A, Lay MK, Mun ̃oz CA, et al. infection. Front Cell Infect Microbiol. 2022;12:949469. [PubMed Central:PMC9548657] [DOI:10.3389/fcimb.2022.949469] [PubMed:26912077].; Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling as- sumptions. Expert Rev Vaccines. 2012 Oct;11(10):1235-47. [DOI:10.1586/erv.12.99] [PubMed:23170992].; Wu DB, Chaiyakunapruk N, Chong HY, Beutels P. Choosing between 7-, 10- and 13- valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014). Vaccine. 2015 Mar;33(14):1633-58. [DOI:10.1016/j.vaccine.2015.01.081] [PubMed:25681663].; Saokaew S, Rayanakorn A, Wu DB, Chaiyakunapruk N. Cost Effectiveness of Pneu- mococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Pharmacoeconomics. 2016 Dec;34(12):1211-25. [DOI:10.1007/s40273-016-0439- 3] [PubMed:19621072].; Syeed MS, Ghule P, Le L, Veettil SK, Horn EK, Perdrizet J, et al. Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-effectiveness Studies. Value Health. 2022 Oct. [DOI:10.1016/j.jval.2022.10.006] [PubMed:36328324].; Chou VB, Friberg IK, Christian M, Walker N, Perry HB. Expanding the population coverage of evidence-based interventions with community health workers to save the lives of mothers and children: an analysis of potential global impact using the Lives Saved Tool (LiST). J Glob Health. 2017 Dec;7(2):020401. [PubMed Central:PMC5592116] [DOI:10.7189/jogh.07.020401] [PubMed:23667340].; Moberg J, Oxman AD, Rosenbaum S, nemann HJ, Guyatt G, Flottorp S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018 May;16(1):45. [PubMed Central:PMC5148903] [DOI:10.1186/s13012-016-0530-3] [PubMed:27938409].; Zhou T, Xie F. Sponsorship bias in oncology cost effectiveness analysis. J Clin Epide- miol. 2023 Feb. [DOI:10.1016/j.jclinepi.2023.02.011] [PubMed:36773749].; World Health Organization. WHO position paper: Pneumococcal conjugate vaccines in infants and children under 5 years of age. WER. 2019 02;94(8):85-104.; Jauregui B, Sinha A, Clark AD, Bolanos BM, Resch S, Toscano CM, et al. Strengthe- ning the technical capacity at country-level to make informed policy decisions on new vaccine introduction: lessons learned by PAHO’s ProVac Initiative. Vaccine. 2011 Jan;29(5):1099-106. [DOI:10.1016/j.vaccine.2010.11.075] [PubMed:21144916].; Cohen JT, Wong JB. Can Economic Model Transparency Improve Provider Interpre- tation of Cost-Effectiveness Analysis? A Response. Med Care. 2017 Nov;55(11):912-4. [DOI:10.1097/MLR.0000000000000811] [PubMed:29028754].; Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low- income and middle-income countries: a novel approach and evidence from cross- country data. BMJ Glob Health. 2018;3(6):e000964. [PubMed Central:PMC6041503] [DOI:10.1016/j.healthpol.2018.04.011] [PubMed:29759682].; https://repositorio.unal.edu.co/handle/unal/84139; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.co/
    • الدخول الالكتروني :
      https://repositorio.unal.edu.co/handle/unal/84139
      https://repositorio.unal.edu.co/
    • Rights:
      Atribución-NoComercial-SinDerivadas 4.0 Internacional ; http://creativecommons.org/licenses/by-nc-nd/4.0/ ; info:eu-repo/semantics/openAccess
    • الرقم المعرف:
      edsbas.6E58465A